It also specifically prompts interrogation of the adaptive immunologic events downstream of the activation of these innate immune sensing pathways, including whether activation of the cGAS-STING pathway within the tumor microenvironment can serve as a predictive biomarker of response to eribulin, particularly in combination with immunotherapy in TNBC. The gene discussed is CGAS; the disease is neoplasm.